124 related articles for article (PubMed ID: 2702979)
1. Survival with breast cancer: the importance of estrogen receptor quantity.
Shek LL; Godolphin W
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):243-50. PubMed ID: 2702979
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients.
Shek LL; Godolphin W; Spinelli JJ
Br J Cancer; 1987 Dec; 56(6):825-9. PubMed ID: 3435707
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptors in primary breast cancer.
Neifeld JP; Lawrence W; Brown PW; Banks WL; Terz JJ
Arch Surg; 1982 Jun; 117(6):753-7. PubMed ID: 7082164
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: a study of 583 patients.
Godolphin W; Elwood JM; Spinelli JJ
Int J Cancer; 1981 Dec; 28(6):677-83. PubMed ID: 7333702
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of estrogen and progesterone receptors in operable breast cancer. Results of a univariate and multivariate analysis.
Chevallier B; Heintzmann F; Mosseri V; Dauce JP; Bastit P; Graic Y; Brunelle P; Basuyau JP; Comoz M; Asselain B
Cancer; 1988 Dec; 62(12):2517-24. PubMed ID: 3191451
[TBL] [Abstract][Full Text] [Related]
6. Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences.
Ruder AM; Lubin F; Wax Y; Geier A; Alfundary E; Chetrit A
Cancer; 1989 Jul; 64(1):196-202. PubMed ID: 2731116
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor protein of breast cancer in patients with positive nodes. High recurrence rates in the postmenopausal estrogen receptor-negative group.
Kinne DW; Butler JA; Kimmel M; Flehinger BJ; Menendez-Botet C; Schwartz M
Arch Surg; 1987 Nov; 122(11):1303-6. PubMed ID: 3675194
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of estrogen receptors determined by radiochemical vs. histochemical methods in breast cancer.
Sismondi P; Aimone V; Genta F; Voglino G; Deltetto F; Giardina G; Botta G; Ghiringhello B; Mano MP; Zola P
Breast Cancer Res Treat; 1985; 6(1):67-73. PubMed ID: 2413929
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the pathologic and prognostic correlates of estrogen receptors in primary breast cancer.
Skinner JR; Wanebo HJ; Betsill WL; Wilhelm MC; Drake CR; Macleod RM
Ann Surg; 1982 Dec; 196(6):636-41. PubMed ID: 7149814
[TBL] [Abstract][Full Text] [Related]
10. Influence of estrogen receptors on survival and recurrence in patients with breast cancer without lymph node metastases.
Maki HS; Hoehn JL
Arch Surg; 1989 Mar; 124(3):377-80. PubMed ID: 2919970
[TBL] [Abstract][Full Text] [Related]
11. Steroid receptors and prognosis in operable (stage I and II) breast cancer.
Stewart JF; Rubens RD; Millis RR; King RJ; Hayward JL
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1381-7. PubMed ID: 6315442
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of estrogen receptor determination in primary breast cancer.
Ciatto S; Palli D; Iossa A; Pacini P; Cataliotti L; Distante V; Teglia C; Caridi G; Messeri G
Radiother Oncol; 1988 Jul; 12(3):187-92. PubMed ID: 3175045
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer.
Alexieva-Figusch J; Van Putten WL; Blankenstein MA; Blonk-Van Der Wijst J; Klijn JG
Cancer; 1988 Feb; 61(4):758-68. PubMed ID: 3338038
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
15. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases.
Williams MR; Todd JH; Ellis IO; Dowle CS; Haybittle JL; Elston CW; Nicholson RI; Griffiths K; Blamey RW
Br J Cancer; 1987 Jan; 55(1):67-73. PubMed ID: 3814477
[TBL] [Abstract][Full Text] [Related]
16. Model for breast cancer survival: relative prognostic roles of axillary nodal status, TNM stage, estrogen receptor concentration, and tumor necrosis.
Shek LL; Godolphin W
Cancer Res; 1988 Oct; 48(19):5565-9. PubMed ID: 3416309
[TBL] [Abstract][Full Text] [Related]
17. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
[TBL] [Abstract][Full Text] [Related]
18. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Albain KS; Green S; LeBlanc M; Rivkin S; O'Sullivan J; Osborne CK
Breast Cancer Res Treat; 1992; 22(3):273-84. PubMed ID: 1391993
[TBL] [Abstract][Full Text] [Related]
19. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up.
Raemaekers JM; Beex LV; Koenders AJ; Pieters GF; Smals AG; Benraad TJ; Kloppenborg PW
Breast Cancer Res Treat; 1985; 6(2):123-30. PubMed ID: 4052639
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor status as a prognostic indicator for stage I breast cancer patients.
Crowe JP; Hubay CA; Pearson OH; Marshall JS; Rosenblatt J; Mansour EG; Hermann RE; Jones JC; Flynn WJ; McGuire WL
Breast Cancer Res Treat; 1982; 2(2):171-6. PubMed ID: 7171837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
